Current location - Trademark Inquiry Complete Network - Tian Tian Fund - 2022 Shaoxing novel coronavirus antigen testing price (novel coronavirus antibody testing price)
2022 Shaoxing novel coronavirus antigen testing price (novel coronavirus antibody testing price)
Shaoxing added the price item of coronavirus antigen detection.

According to the spirit of the Notice of Zhejiang Medical Security Bureau on Doing a Good Job in Medical Security for Current Epidemic Prevention and Control, since March 25th, Shaoxing City has added a novel coronavirus antigen test price according to the notice of the provincial bureau.

It is clear that the price of antigen testing in public medical institutions is 5 yuan/time, and the sales of antigen testing reagents are zero price difference, and the fees are charged according to the method of "antigen testing items+testing reagents", and the total fees do not exceed 15 yuan/time.

Public medical institutions that simply carry out antigen testing shall not charge outpatient consultation fees and general consultation fees; Patients who are tested by themselves shall not be charged novel coronavirus antigen testing fees.

Novel coronavirus antigen testing items and testing reagents in designated primary medical institutions are temporarily included in the medical insurance fund payment, and are managed according to Class A, and the payment scope is limited to patients with fever clinic or novel coronavirus imaging characteristics.

Patients in the designated retail pharmacies to buy novel coronavirus antigen detection reagent costs, included in the basic medical insurance for employees over the years personal account payment. The balance of personal accounts over the years can be used to pay the expenses for the immediate family members of the insured to buy novel coronavirus antigen detection reagents in the designated retail pharmacies of medical insurance.

In addition, the novel coronavirus drugs included in the scope of medical insurance payment were adjusted, and the drugs out of the medical insurance catalogue included in the novel coronavirus diagnosis and treatment plan of the National Health and Wellness Commission were temporarily included in the scope of medical insurance fund payment, and they were managed according to Class A. Under the condition that the provincial medical device procurement platform was not online, public medical institutions were allowed to purchase offline to meet the people's antigen testing needs.